Jeffrey Peppercorn, MD, MPH

Jeffrey Peppercorn, MD, MPH

Research Interests: Issues related to quality of care and survivorship for patients with breast cancer as well as health policy and bioethics issues related to oncology.

Overview

Biography

Dr. Peppercorn is a hematologist/oncologist with special interests in breast cancer, medical ethics, and health policy. He trained at Harvard Medical School, completed internal medicine residency at Massachusetts General Hospital, and completed his hematology/oncology fellowship training at the Dana-Farber Cancer Institute. His clinical specialty is breast cancer and he is currently an Associate Professor of Medicine at Harvard University and the Director of the Cancer Survivorship Program at Massachusetts General Hospital. He also chairs the Ethics committee of the Alliance for Clinical Trials in Oncology and serves as a member of the ASCO Task Force on Value in Cancer Care. He is a Greenwall Foundation Faculty Scholar in Bioethics.

Research Interests

His research focuses on issues related to quality of care and survivorship for patients with breast cancer as well as health policy and bioethics issues related to oncology. He is the author of over 100 publications, reviews, and chapters on these topics.

Publications

Selected Publications

  1. Peppercorn J, Smith TJ, Helft PR, DeBono DJ, Berry SB, Lyckholm LJ, Wollins D, Hayes DM, Vonn Roenn JH, Schnipper LE. ASCO Statement: Towards Individualized Care for Patients with Advanced Cancer. J Clin Oncol. 2011 Feb 20;29(6):755-60. Epub 2011 Jan 24.
  2. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011 Sep;12(10):933-80.
  3. Peppercorn J, Shapira I, Collyar DH, et al. on Behalf of the Cancer and Leukemia Group B (CALGB) The Ethics of Mandatory Research Biopsy for Correlative Endpoints within Clinical Trials in Oncology. J Clin Oncol. 2010, May 20;28(15):2635-40. Epub 2010 Apr 20.
  4. Peppercorn J, Hamilton EP, Marcom PK, Beskow L, Lyman GH. Pharmacogenetic Testing In the Face of Unclear Clinical Efficacy: Lessons from CYP2D6 for Tamoxifen. Cancer. 2013 Oct 15;119(20):3703-9.
  5. Peppercorn J, Zafar SY, Houck K, Ubel P, Meropol N. Does Comparative Effectiveness Research Promote Rationing of Cancer Care? Lancet Oncol. 2014 Mar;15(3):e132-8.
  6. Peppercorn J, Houck K, Beri N, Villagra V, Wogu AF, Lyman GH, Wheeler SB. Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance. Breast Cancer Res Treat. 2015 Oct;153(3):659-67.

Back to Top